TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03467971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin/Gliclazide Fixed Combination
Description: Participants will receive single oral dose of Metformin 1000 mg and Gliclazide 30 mg fixed combination tablet in fasting or fed state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin/Gliclazide Fixed Combination
Description: Participants will receive single oral dose of Metformin 1000 mg and Gliclazide 30 mg fixed combination tablet in fasting or fed state.
Study: NCT00481871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralatrexate Injection
Description: Intravenous (IV) push administration over 30 seconds to 5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).~Sequential Dosing: 10 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met.~Same Day Dosing: 15 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralatrexate Injection
Description: Intravenous (IV) push administration over 30 seconds to 5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).~Sequential Dosing: 10 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met.~Same Day Dosing: 15 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met.
Study: NCT01116817

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar puncture (HAART: Lopinavir/ritonavir + 2 NRTI)
Description: Lumbar puncture at week 0
Study: NCT02652728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril Orodispersible Minitablet
Description: Weight-dependent dose titration and long-term treatment scheme with enalapril ODMTs of 0.25 mg and 1 mg strength
Study: NCT00930111

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2-week rotation
Description: Attending physician is assigned to a 2-week rotation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 4-week rotation
Description: Attending physician is assigned to a 4-week rotation.
Study: NCT02649686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study: NCT03073603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Discontinuation of disease modifying therapy
Description: Participants who will discontinue their current MS drug. No other changes to their treatment occur.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants who remain on their current Disease Modifying Therapies (DMTs) without any changes. DMTs include \~14 formulations/doses of drugs approved in the US by the FDA that alter the natural history of the disease.
Study: NCT01177111

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunflower seed oil
Description: Locally manufactured refined sunflower seed oil will be provided to pregnant women late in pregnancy and community workers will promote its daily use during massage of newborns during the first month of life

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mustard seed oil
Description: Locally manufactured mustard seed oil will be provided to pregnant women late in pregnancy and community workers will promote its daily use during massage of newborns during the first month of life
Study: NCT01391104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Sildenafil citrate is a phosphodiesterase type-5 inhibitor. Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
Study: NCT01181934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A643 (nicotine)
Description: 2mg oromucosal nicotine spray- three times daily during each treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo - three times daily during each treatment period
Study: NCT00481871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Gemcitabine will be prepared and administered as an IV infusion as per manufacturer instructions.~Sequential Dosing: 400 mg/m2 every 2 weeks (days 2 and 16) of a 4-week cycle until criteria for discontinuation per the protocol are met.~Same Day Dosing: 600 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met.
Study: NCT01181934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A643 (nicotine)
Description: 1mg oromucosal nicotine spray- three times daily during each treatment period
Study: NCT00006172

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bright light box
Description: 60-min light therapy shortly after awakening

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-output negative ion generator
Description: 60-min high-density ion exposure shortly after awakening

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Low-output negative ion generator
Description: 60-min low-density ion exposure shortly after awakening
Study: NCT01480700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional study
Description: subjects consume 2 eggs per day during 4 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional study
Description: subjects consume 2 eggs per day during 4 months
Study: NCT00455195

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alglucosidase alfa
Description: IV infusion of 20 mg/kg; every other week (qow)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alglucosidase alfa
Description: IV infusion of 20 mg/kg; every other week (qow)
Study: NCT04434404

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Carnitine 500Mg Oral Tablet
Description: eighty-three eligible patients were recruited 33, 25, and 25 patients in the control group, L-carnitine group, and, Silymarin group respectively, completed the study~without cardioprotective agents in a dose of 50 mg/m2. L-carnitine group received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus L-carnitine 3 gm L-carnitine® capsules obtained from (MEPACO) was taken PO one day before chemotherapeutic cycle and 1gm /day during the following 21 days. Silymarin group received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus Silymarin as cardioprotective agent.140 mg (Legalon ® 140 mg capsule obtained from (MEDA). Silymarin was taken PO once daily after meals during the chemotherapeutic cycle. The treatment period was 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Carnitine 500Mg Oral Tablet
Description: eighty-three eligible patients were recruited 33, 25, and 25 patients in the control group, L-carnitine group, and, Silymarin group respectively, completed the study~without cardioprotective agents in a dose of 50 mg/m2. L-carnitine group received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus L-carnitine 3 gm L-carnitine® capsules obtained from (MEPACO) was taken PO one day before chemotherapeutic cycle and 1gm /day during the following 21 days. Silymarin group received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus Silymarin as cardioprotective agent.140 mg (Legalon ® 140 mg capsule obtained from (MEDA). Silymarin was taken PO once daily after meals during the chemotherapeutic cycle. The treatment period was 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: L-Carnitine 500Mg Oral Tablet
Description: eighty-three eligible patients were recruited 33, 25, and 25 patients in the control group, L-carnitine group, and, Silymarin group respectively, completed the study~without cardioprotective agents in a dose of 50 mg/m2. L-carnitine group received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus L-carnitine 3 gm L-carnitine® capsules obtained from (MEPACO) was taken PO one day before chemotherapeutic cycle and 1gm /day during the following 21 days. Silymarin group received anthracycline-containing chemotherapy in a dose of 50 mg/m2 plus Silymarin as cardioprotective agent.140 mg (Legalon ® 140 mg capsule obtained from (MEDA). Silymarin was taken PO once daily after meals during the chemotherapeutic cycle. The treatment period was 6 months.
Study: NCT02250404

Intervention type: OTHER
Intervention: cytology specimen collection procedure
Description: Correlative studies

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01019330

Intervention type: OTHER
Intervention: Allen's test
Description: The Allen's test checks to make sure that radial and ulnar arteries that supply blood to the hand are not blocked. A pulse oximeter is placed on the index finger of the hand. The subject is asked to make a fist for 10 seconds.At this time, pressure is applied over the ulnar and radial arteries as to occlude (block) both of them. The pulse oximeter reading will begin to fall. Radial arterial pressure is then released. If the artery is patent (working), the pulse oximeter reading will begin to rise.
Study: NCT00481871

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: 1 mg intramuscular injection~Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: 1 mg intramuscular injection~Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: 1 mg orally~Administered daily for at least 7 days prior to start of pralatrexate, throughout the study and for at least 30 days after last dose of pralatrexate.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: 1 mg orally~Administered daily for at least 7 days prior to start of pralatrexate, throughout the study and for at least 30 days after last dose of pralatrexate.
Study: NCT03084978

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: General anesthesia by standard endotracheal intubation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conscious Sedation
Description: Conscious sedation
Study: NCT01395693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Salt Lake mask system
Description: Study participants will Salt Lake mask system for 1 week in place of their current mask system.
Study: NCT02522949

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ColdZyme® mouth spray

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00769015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BA-LVR
Description: Low vision clinic-based optometry plus 6 in-home occupational therapy visits

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: ST-LVR
Description: Clinic-based low vision optometry plus 6 in-home sessions of Supportive Therapy
Study: NCT02020655

Intervention type: OTHER
Intervention: Shear- force model
Description: Shear- force model
Study: NCT05073263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Patient is randomized to the weightbearing group the day after surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Patient is randomized to the weightbearing group the day after surgery.
Study: NCT05224297

Intervention type: RADIATION
Intervention: external beam photon therapy
Description: Patients receive external beam photon therapy for different tumor locations (groups).

Intervention type: RADIATION
Intervention: external beam photon therapy
Description: Patients receive external beam photon therapy for different tumor locations (groups).

Intervention type: RADIATION
Intervention: external beam photon therapy
Description: Patients receive external beam photon therapy for different tumor locations (groups).

Intervention type: RADIATION
Intervention: external beam photon therapy
Description: Patients receive external beam photon therapy for different tumor locations (groups).

Intervention type: RADIATION
Intervention: external beam photon therapy
Description: Patients receive external beam photon therapy for different tumor locations (groups).

Intervention type: RADIATION
Intervention: external beam photon therapy
Description: Patients receive external beam photon therapy for different tumor locations (groups).

Intervention type: RADIATION
Intervention: external beam photon therapy
Description: Patients receive external beam photon therapy for different tumor locations (groups).
Study: NCT01019330

Intervention type: OTHER
Intervention: Distal pulses
Description: Practitioner will check that the dorsalis pedis and posterior tibialis are palpable.
Study: NCT01186523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long Term Energy Balance
Description: To see if there is a variance in weight loss and energy balance between men and women with similar energy expenditure over an extended period of time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long Term Energy Balance
Description: To see if there is a variance in weight loss and energy balance between men and women with similar energy expenditure over an extended period of time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long Term Energy Balance
Description: To see if there is a variance in weight loss and energy balance between men and women with similar energy expenditure over an extended period of time.
Study: NCT04475601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide Pill
Description: The once daily dose will be given only during hospitalization and stop if starting invasive mechanical ventilation or at discharge from hospital
Study: NCT05224297

Intervention type: RADIATION
Intervention: external beam photon therapy
Description: Patients receive external beam photon therapy for different tumor locations (groups).

Intervention type: RADIATION
Intervention: external beam photon therapy
Description: Patients receive external beam photon therapy for different tumor locations (groups).
Study: NCT03377387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be taken orally in AM and PM (at the assigned dose per cohort) 7 days on and 7 days off. Phase II MD 1000mg BID of capecitabine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Neratinib is given as 240 mg daily continuously without stopping. A cycle is 28 days. Phase II The MD has been determined as 240mg of neratinib

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EORTC QLQ - BR23, EQ-5D-5L, EORTC QLQ-C30
Description: Questionnaires Every Cycle (+/- 3 days) (For phase II)
Study: NCT00509340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: Participants in this group will receive individual sessions of cognitive-behavioral training for improvement of medication adherence and reduction of depression.
Study: NCT01514409

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5-Hydroxytryptophan
Description: Thirty-three participants were randomly allocated in a double-blind manner to receive either 3x50mg capsules of 5-HTP or placebo (silica) for 14 days.~5-HTP is produced commercially by extraction from the seeds of the African plant griffonia simplicifolia.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pharmaceutical grade silica
Description: Pharmaceutical grade silica was utilized as placebo
Study: NCT03202186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone oral capsule
Description: Oral capsule treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone oral capsule
Description: Oral capsule treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone oral capsule
Description: Oral capsule treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Oral capsule treatment
Study: NCT04434638

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transitions of Care Coordinator
Description: We developed the Transition of Care Coordinator (TOCC) program to aid in the completion of the diagnostic evaluations as well as in the transition out of the acute care hospital setting. In the TOCC intervention, the stroke nurse navigator completed eight specific tasks: (1) met the patient and family within 48 hours of admission, (2) identified patient home location and insurance status, (3) coordinated communication between treating providers (neurologists, cardiologists, etc.) regarding pending diagnostic tests, (4) followed up physical, occupational, and speech therapy teams' recommendations for rehabilitation, (5) attended daily multi-disciplinary rounds, (6) facilitated referrals to acute and subacute rehabilitation facilities with case managers, (7) assisted beside nurses in providing tailored stroke education and discharge instructions to patients and families, and (8) arranged stroke clinic follow-up appointments.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients received the current, ongoing method of care coordination by members of the multi-disciplinary stroke team. The current practice is that members of this multi-disciplinary team meet with each other every weekday morning to discuss the discharge plan of care for each stroke patient on the inpatient stroke service. Physicians, nurses, rehabilitation therapists and case managers are then individually responsible for talking to patients and their families/caregivers about the different aspects of the plan of care.
Study: NCT01770678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constraint Induced Movement Therapy
Description: A combination of prolonged restraint of the unaffected upper limb and massed practice of the affected upper limb.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Constraint Induced Movement Therapy
Description: A combination of prolonged restraint of the unaffected upper limb and massed practice of the affected upper limb.
Study: NCT02756078

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TEST Contact Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TEST Contact Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL Contact Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL Contact Lens
Study: NCT03839784

Intervention type: COMBINATION_PRODUCT
Intervention: Neurocognition Interventions
Description: EEG, Neurocognitive Battery Testing, and Immune Profiles
Study: NCT01141049

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: During week 1 the dosage will be increased 3 times. Days 1 and 2, participants will receive 400 mg of Gabapentin three times daily. During days 3 and 4 the dosage will be increased to 800 mg three times daily. On day 5 through 7, participants will receive a dose of 1200 mg three times daily, which will continue from week 2 through 8. During week 9 patients will be tapered off for the duration of the week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, TID
Study: NCT01257828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: riluzole
Description: 50mg BID orally for 14 days prior to surgery and 28 days after the surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo medication
Description: 50mg BID orally for 14 days prior to surgery and 28 days after the surgery
Study: NCT02349009

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-82 Topical Gel, 1%
Description: active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: C-82 Topical Gel, Placebo
Description: placebo
Study: NCT02523729

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anke Malz
Description: non-alcoholic malt drink

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anke Malz
Description: non-alcoholic malt drink
Study: NCT04167280

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipratropium Metered Dose Inhaler
Description: MDI to deliver 20mcg per puff ipratropium bromide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo metered dose inhaler
Description: matched MDI to deliver inactive drug
Study: NCT01651494

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DAS181
Description: DAS181-F04 is a recombinant neuraminidase that is delivered onto the cell surface of the upper and central airway topically and locally through an inhaler as an encapsulated dry powder. DAS181-F04; 20 mg single-dose each day via oral inhalation for 3 days; 6 subjects

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: White to off-white powder with Lactose Monohydrate and 5 % moisture; 20 mg single-dose each day via oral inhalation for 3 days; 3 subjects
Study: NCT04276285

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic TAP
Description: Subcostal TAP block will be performed after surgery under laparoscopic guidance

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US TAP
Description: Subcostal TAP block will be performed after surgery under US guidance
Study: NCT01637259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors
Description: NRTI + PI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2 boosted protease inhibitors and maraviroc
Description: PI + maraviroc

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc
Description: NRTI + maraviroc
Study: NCT00136734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03174509

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positive pressure extubation
Description: Positive pressure ventilation without endotracheal aspiration/suction during extubation procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional during extubation
Description: Spontaneous ventilation with endotracheal aspiration/suction during extubation procedure.